News & AnalysisAmbrx pulls in $200mCalifornia-based Ambrx Inc, a clinical-stage biopharmaceutical company, has raised $200 million in financing.ByIris Dorbian10 November 2020•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs